Novartis (NVS) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Novartis (NYSE: NVS):

• 10/31/2026 – Novartis was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/30/2026 – Novartis was downgraded by Deutsche Bank Aktiengesellschaft from “hold” to “sell”.
• 10/28/2026 – Novartis had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 10/28/2026 – Novartis had its “neutral” rating reaffirmed by UBS Group.
• 10/28/2026 – Novartis had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $163.00 price target on the stock.
• 10/28/2026 – Novartis is now covered by DZ Bank. They set a “hold” rating on the stock.
• 10/22/2026 – Novartis had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 10/6/2026 – Novartis had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $156.00 price target on the stock.
• 9/21/2026 – Novartis had its “sell” rating reaffirmed by The Goldman Sachs Group.
• 9/17/2026 – Novartis had its “neutral” rating reaffirmed by UBS Group.
• 9/17/2026 – Novartis had its “neutral” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 9/11/2026 – Novartis had its price target lowered by Berenberg Bank from $147.00 to $130.00. They now have a “hold” rating on the stock.
• 9/10/2026 – Novartis was upgraded by HSBC from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
• 9/10/2026 – Novartis was upgraded by HSBC from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
• 9/8/2026 – Novartis was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
• 9/8/2026 – Novartis is now covered by Royal Bank Of Canada. They set a “sector perform” rating on the stock.
• 9/8/2026 – Novartis had its “buy” rating reaffirmed by Bank of America.

Novartis Trading Up 2.8%

Shares of NYSE NVS opened at $163.64 on Wednesday. Novartis AG has a 1-year low of $123.24 and a 1-year high of $170.46. The company has a 50-day moving average of $148.48 and a two-hundred day moving average of $151.96. The company has a market cap of $312.25 billion, a PE ratio of 31.23, a P/E/G ratio of 2.97 and a beta of 0.40. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.25 by $0.21. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.53 billion. During the same period last year, the firm earned $2.25 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. As a group, equities analysts expect that Novartis AG will post 9.04 earnings per share for the current fiscal year.

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.